The Medicines Co. price target raised to $37 from $34 at Leerink

Leerink raised its price target for The Medicines Co. after the company announced positive Phase 3 results of the PHOENIX trial of Cangrelor. The firm estimates Cangrelor could address a $200M U.S. market opportunity and reiterates an Outperform rating on the stock.

View Comments (0)